Rein Therapeutics Inc.
RNTX
$1.76
-$0.15-7.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.86M | 16.72M | 16.33M | 12.92M | 11.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.11M | 29.62M | 25.52M | 18.56M | 15.35M |
| Operating Income | -28.11M | -29.62M | -25.52M | -18.56M | -15.35M |
| Income Before Tax | -64.43M | -29.24M | -25.22M | -18.07M | -15.73M |
| Income Tax Expenses | -1.54M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.88 | -29.24 | -25.22 | -18.07 | -15.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.88M | -29.24M | -25.22M | -18.07M | -15.73M |
| EBIT | -28.11M | -29.62M | -25.52M | -18.56M | -15.35M |
| EBITDA | -28.05M | -29.50M | -25.40M | -18.43M | -15.23M |
| EPS Basic | -3.46 | -3.11 | -3.25 | -3.19 | -3.39 |
| Normalized Basic EPS | -1.14 | -1.95 | -2.03 | -2.01 | -1.99 |
| EPS Diluted | -3.46 | -3.11 | -3.25 | -3.19 | -3.39 |
| Normalized Diluted EPS | -1.14 | -1.95 | -2.03 | -2.01 | -1.99 |
| Average Basic Shares Outstanding | 71.57M | 54.65M | 37.52M | 22.15M | 18.39M |
| Average Diluted Shares Outstanding | 71.57M | 54.65M | 37.52M | 22.15M | 18.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |